Edgewise Therapeutics, Inc.

NASDAQ•EWTX

CEO: Dr. Peter A. Thompson FACP, M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-03-26

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Contact Information

1715 38th Street, Boulder, CO, 80301, United States

720-262-7002

www.edgewisetx.com

Market Cap

$3.75B

P/E (TTM)

-21.2

24.5

Dividend Yield

52W High

$40.77

52W Low

$12.15

52W Range

79%

Rank53Top 76.1%

2.8

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q1 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.46+0.00%

4-Quarter Trend

FCF

-$42.80M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Widens Substantially Net loss reached $167.8M USD in 2025, up $34.0M from 2024; total operating expenses increased $32.6M to $191.4M USD.

R&D Spending Ramps Up Research and development expenses totaled $151.4M USD in 2025, increasing $24.4M, driven by sevasemten and EDG-7500 clinical activities.

Cash Position Maintained Cash, equivalents, and securities totaled $530.1M USD as of December 31, 2025, supported by recent registered direct offerings.

Pipeline Advancement Continues Sevasemten trials ongoing in Becker/Duchenne; EDG-7500 in multipart Phase 2 HCM trial; EDG-15400 entered Phase 1.

Risk Factors

High Operating Losses Continue Incurred $167.8M USD net loss for 2025; no revenue generated to date; expects significant losses for foreseeable future.

Need Substantial Additional Capital Substantial additional capital required to fund operations; failure to raise funds delays development or eliminates research programs.

Clinical Development Outcome Uncertain Clinical trial results are uncertain; success of lead candidates sevasemten and EDG-7500 substantially impacts business viability.

Competition Threatens Market Share Faces significant competition from established firms; competitors developing safer, more effective, or less expensive therapies.

Outlook

Advance Key Clinical Programs Continue advancing sevasemten in muscular dystrophies and EDG-7500 in HCM through ongoing and planned clinical trials.

Initiate EDG-15400 Phase Two Plans to initiate Phase 2 trial for EDG-15400 in HFpEF patients in the second half of 2026, following Phase 1 completion.

Expect Increased Operating Expenses Anticipates general and administrative expenses will increase as organization scales to support clinical advancement and regulatory readiness.

Secure Future Capital Requirements Future funding needs depend on R&D progress, regulatory review costs, and market conditions; substantial additional funding required.

Peer Comparison

Revenue (TTM)

GLPG

$1.21B

+262.2%

HRMY

$899.11M

+20.7%

NVAX

$596.34M

-52.5%

Gross Margin (Latest Quarter)

WVE

100.0%

+0.0pp

QURE

93.9%

+33.9pp

NUVB

93.3%

+182.9pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
EWTX	$3.75B	-21.2	-32.5%	0.7%
VERA	$2.46B	-6.6	-74.9%	12.1%
RCUS	$2.40B	-8.1	-69.0%	10.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data